Clinical trials
Observational Renal Insufficiency, Chronic trials in Turkey (Türkiye)
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
31 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 3 |
| 2011 | 5 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 5 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 5 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 16 |
| Recruiting | 6 |
| Unknown status | 5 |
| Not yet recruiting | 3 |
| Enrolling by invitation | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hacettepe University | 5 |
| Ankara Education and Research Hospital | 2 |
| Haseki Training and Research Hospital | 2 |
| Heidelberg University | 2 |
| Uşak University | 2 |
| AbbVie (prior sponsor, Abbott) | 1 |
| Acibadem University | 1 |
| Ankara City Hospital Bilkent | 1 |
| Ankara Diskapi Training and Research Hospital | 1 |
| Corum State Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Renal Insufficiency, Chronic | 31 |
| Kidney Failure, Chronic | 5 |
| Inflammation | 4 |
| COVID-19 | 2 |
| Cardiovascular Diseases | 2 |
| Diabetes Mellitus | 2 |
| Hypertrophy, Left Ventricular | 2 |
| Periodontitis | 2 |
| Vascular Diseases | 2 |
| Acute Coronary Syndrome | 1 |
Trials
Showing 1 to 25 of 31. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.